by: Ryan Fischer, Chief Advocacy Officer
Today, PPMD launched a survey to gain insight directly from the Duchenne and Becker community on the impact of the COVID-19 pandemic related to care, clinical trials, and access to FDA approved therapies.
This information is vital to informing the work of relevant stakeholder groups in the Duchenne and Becker community including physicians, drug developers, and patient advocacy groups. PPMD plans to share the results with the community later this spring.
The survey should take around 15-20 minutes to complete. Your personal information will not be shared with anyone.
Complete the SurveyIf you have questions about the survey please contact Ryan Fischer.
